These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8205527)
1. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Otto T; Birchmeier W; Schmidt U; Hinke A; Schipper J; Rübben H; Raz A Cancer Res; 1994 Jun; 54(12):3120-3. PubMed ID: 8205527 [TBL] [Abstract][Full Text] [Related]
2. Improved prognosis assessment for patients with bladder carcinoma. Otto T; Bex A; Schmidt U; Raz A; Rübben H Am J Pathol; 1997 Jun; 150(6):1919-23. PubMed ID: 9176385 [TBL] [Abstract][Full Text] [Related]
3. [Principles of tumor invasion and metastasis]. Otto T; Goepel M; Recker F; Rübben H Urologe A; 1995 May; 34(3):208-11. PubMed ID: 7610514 [TBL] [Abstract][Full Text] [Related]
4. Motility- and adhesion factors in bladder carcinoma. Otto T; Goepel M; Enzwi SM; Meyer-Schwickerath M; Rübben H Investig Urol (Berl); 1994; 5():80-4. PubMed ID: 7719326 [No Abstract] [Full Text] [Related]
5. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734 [TBL] [Abstract][Full Text] [Related]
6. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Nakamori S; Watanabe H; Kameyama M; Imaoka S; Furukawa H; Ishikawa O; Sasaki Y; Kabuto T; Raz A Cancer; 1994 Oct; 74(7):1855-62. PubMed ID: 8082090 [TBL] [Abstract][Full Text] [Related]
7. Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Maruyama K; Watanabe H; Shiozaki H; Takayama T; Gofuku J; Yano H; Inoue M; Tamura S; Raz A; Monden M Int J Cancer; 1995 Oct; 64(5):316-21. PubMed ID: 7591303 [TBL] [Abstract][Full Text] [Related]
8. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629 [TBL] [Abstract][Full Text] [Related]
9. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Hirono Y; Fushida S; Yonemura Y; Yamamoto H; Watanabe H; Raz A Br J Cancer; 1996 Dec; 74(12):2003-7. PubMed ID: 8980404 [TBL] [Abstract][Full Text] [Related]
10. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884 [TBL] [Abstract][Full Text] [Related]
11. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571 [TBL] [Abstract][Full Text] [Related]
12. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602 [TBL] [Abstract][Full Text] [Related]
13. Expression of E-cadherin and alpha-,beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Mialhe A; Louis J; Montlevier S; Peoch M; Pasquier D; Bosson JL; Rambeaud JJ; Seigneurin D Invasion Metastasis; 1997; 17(3):124-37. PubMed ID: 9702939 [TBL] [Abstract][Full Text] [Related]
14. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520 [TBL] [Abstract][Full Text] [Related]
15. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer. Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027 [TBL] [Abstract][Full Text] [Related]
16. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551 [TBL] [Abstract][Full Text] [Related]
17. Suppression of melanoma cell motility factor receptor expression by retinoic acid. Lotan R; Amos B; Watanabe H; Raz A Cancer Res; 1992 Sep; 52(18):4878-84. PubMed ID: 1325286 [TBL] [Abstract][Full Text] [Related]
18. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367 [TBL] [Abstract][Full Text] [Related]
19. Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. Giroldi LA; Bringuier PP; Schalken JA Invasion Metastasis; 1994-1995; 14(1-6):71-81. PubMed ID: 7657535 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of N-E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes]. Cui D; Han BM; Jing YF; Xia SJ Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):380-3. PubMed ID: 22490896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]